Protocol Ledger

NCT06230354 · Phase II · ACTIVE NOT RECRUITING

Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis

Interventional Phase II clinical trial protocol NCT06230354 sponsored by Imperial College London in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-15 Enrollment: 42 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06230354
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)42 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06230354
Protocol FieldVerified Registry Value
NCT IdentifierNCT06230354
Consolidated Lead SponsorImperial College London
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment42 participants (ACTUAL)
Registered Start Date2024-05-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06230354
Hospital Research SiteLocationSite Profile
University Hospitals Birmingham NHS Foundation TrustBirmingham, United KingdomOpen Hospital Dossier ->
Barts Health NHS TrustLondon, United KingdomOpen Hospital Dossier ->
Imperial College Healthcare NHS TrustLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI